Inventiva S.A. - IVA Net earnings per share (EPS TTM)

Corporate company logo of Inventiva Corp (IVA)

Inventiva S.A. relies on clinical drug development cycles that remain independent of macroeconomic trends. The 12-month EPS change on the GURU.Markets terminal chart reflects the current metric -1.36. The company's prospects are based on a unique steatohepatitis therapy that provides access to a massive market. However, geopolitical risks may complicate patent protection and the import of raw materials.

IVA Inventiva Corp Earnings per share for the trailing year (07/04/2022 - 11/12/2026)

Financial and market metric breakdowns for Inventiva SA (IVA)

- share price and expert price forecast:
Stock Quotes Inventiva S.A.|IVA - Price Target Chart
- issuer market value details:
Market Capitalization Inventiva S.A.|IVA - Total Enterprise Value
- business book valuation details:
Net Assets per Single Share Inventiva|IVA - Accounting Value of Company|Market Capitalization to Book Value Ratio inventivapharma.com|IVA - Company Total Asset Base
- debt and liquidity details:
Debt to Equity Inventiva S.A.|IVA - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Inventiva Pharma|IVA - Company Debts|Debts to Book Capitalization Inventiva S.A.|IVA - Long-Term Debt|Company Short-Term Debt Inventiva|Quick Liquidity Indicator inventivapharma.com
- earnings and multiples data:
IVA - Profit After Payment of Taxes|Projected Future Earnings Inventiva S.A.|IVA - Business Payback Period|Projected Price to Earnings Inventiva|IVA - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Inventiva S.A.|IVA - Operating profit EBITDA|Net earnings per share for the last 12 months Inventiva|IVA - Earnings per share for the trailing year|Year-over-year earnings per share growth for the last twelve months inventivapharma.com|IVA - Expected net earnings per share growth this year|Expected earnings per share growth for next year Inventiva S.A.
Fundamental company valuation:Inventiva S.A. (IVA)
Mass-produced product of Inventiva Corp

To minimize investment risks, Inventiva S.A. must evaluate the efficiency of profit generation relative to capital. This metric is calculated as the ratio of total annual net income to the number of shares, and analyzing the annual net income per share chart allows for a correlation between the business's financial stability and its commitment to ESG standards and biotechnological development ethics.

Main competitors

ARWR: Net earnings per share for the last 12 months|MIRM: Earnings per share for the last twelve months|DVAX: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Arbutus Biopharma Corp (ABUS)|Earnings per share for the last twelve months Gyre Corp|ASMB: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GALT|Net earnings per share for the last four quarters genfit.com|Earnings per share for the last twelve months DURECT DRRX|ALGS: Earnings per share for the last 12 months|BIVI: Net earnings per share for the last 12 months|GLMD: Earnings per share for the last twelve months|NDRA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Hepion Pharmaceuticals, Inc. (HEPA)